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Abstract
We propose a robust two-stage design to identify the optimal biological dose for phase I/II clinical 
trials evaluating both toxicity and efficacy outcomes. In the first stage of dose finding, we use the 
Bayesian model averaging continual reassessment method to monitor the toxicity outcomes and 
adopt an isotonic regression method based on the efficacy outcomes to guide dose escalation. 
When the first stage ends, we use the Dirichlet-multinomial distribution to jointly model the 
toxicity and efficacy outcomes and pick the candidate doses based on a three-dimensional volume 
ratio. The selected candidate doses are then seamlessly advanced to the second stage for dose 
validation. Both toxicity and efficacy outcomes are continuously monitored so that any overly 
toxic and/or less efficacious dose can be dropped from the study as the trial continues. When the 
phase I/II trial ends, we select the optimal biological dose as the dose obtaining the minimal value 
of the volume ratio within the candidate set. An advantage of the proposed design is that it does 
not impose a monotonically increasing assumption on the shape of the dose-efficacy curve. We 
conduct extensive simulation studies to examine the operating characteristics of the proposed 
design. The simulation results show that the proposed design has desirable operating 
characteristics across different shapes of the underlying true dose-toxicity and dose-efficacy 
curves. The software to implement the proposed design is available upon request.
Keywords
dose-finding; optimal biological dose; Bayesian adaptive design; isotonic regression; Phase I/II 
design
1. Introduction
The primary goal of a phase I clinical trial for cytotoxic agents is typically to identify the 
maximum tolerated dose (MTD) based on the toxicity outcomes. Then, a phase II trial often 
follows to examine the efficacy of the drug at the identified MTD or the recommended dose 
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level. Conventionally, phase I and phase II trials are carried out separately. However, for the 
purpose of streamlining the drug development process and reducing the associated time and 
cost, there is a growing trend to integrate phase I and phase II trials into one trial. Several 
seamless phase I/II trial designs that jointly model the efficacy and toxicity outcomes of 
cytotoxic agents are available in the literature [1, 2, 3, 4, 5, 6].
Traditional dose-finding designs for cytotoxic agents, including the commonly used 3+3 
design [7] and continual reassessment method (CRM) [8], assume that both efficacy and 
toxicity outcomes increase monotonically with the dose. However, the recent development 
of novel molecularly targeted agents (MTAs) challenges the traditional paradigm of dose-
finding designs because the assumption of a monotonically increasing dose-efficacy 
relationship may not hold for MTAs. Many of the MTAs block the division of cancer cells 
by identifying and attacking specific pathways involved in tumor growth. As a result, the 
toxicity of MTAs can be minimal within the therapeutic dose range, and the dose-efficacy 
curves of MTAs may not follow monotonic patterns [9, 10, 11, 12]. For example, Friedman 
et al.[13] conducted a phase I trial for patients undergoing craniotomy for malignant glioma 
who received an MTA, O6-benzylguanine (O6-BG). In that trial, the efficacy of the agent 
was measured by the activity of the target enzyme O6-alkylguanine-DNA alkyltransferase 
(AGT). The goal of the trial was to find the dose required to deplete tumor AGT activity in 
five O6-BG dose levels ranging from 40 mg/m2 to 120 mg/m2. The agent demonstrated 
minimal toxicity and a non-monotonic dose-response relationship. A total of 30 patients 
were enrolled in the trial and only one observation of toxicity was reported. At the end of the 
trial, dose level 4 at 100 mg/m2 was selected as the most efficacious dose.
Hence, a more reasonable goal of dose-finding trial designs for MTAs is finding the optimal 
biological dose (OBD), which is defined as the dose that has a desirable efficacy 
performance while still safeguarding patients with an acceptable toxicity profile [3, 14]. The 
OBD of an MTA is not always the highest dose and may appear in the middle of the 
investigational dose range. In practice, the dose-efficacy curves for MTAs are often expected 
to be unimodal or to plateau within the therapeutic dose range. Several dose-finding clinical 
trial designs that identify the OBD for MTAs have been proposed. For example, Braun [15] 
developed the bivariate CRM (bCRM) model by extending the traditional CRM with a 
flexible bivariate distribution that jointly models both the toxicity and efficacy outcomes. 
Hunsberger et al. [16] proposed the slope-sign design to guide dose finding based on the 
sign of the estimated local dose-efficacy curve. Zhang et al. [17] proposed the trinomial 
CRM to find the OBD; this method was further extended by Mandrekar et al. [18] for drug 
combination trials. Recently, Zang et al. [19] proposed three adaptive dose-finding designs 
for trials that evaluate MTAs.
Due to the non-monotonic dose-efficacy curve for MTAs and relatively small sample size of 
phase I trials, the toxicity-efficacy profiles of the candidate doses identified from phase I 
trials often retain a high level of uncertainty. Hence, a phase II dose-validation trial should 
follow to further validate the response profiles of the candidate doses and select the optimal 
dose. However, in spite of the rich body of literature on phase I dose-finding trial designs for 
MTAs [15, 16, 17, 18, 19], limited research has been conducted on seamless phase I/II 
designs integrating both dose-finding and dose-validation schemes for MTAs. Recently, 
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Hoering et al. [14, 20] proposed an integrated phase I/II trial design to assess the toxicity 
and efficacy outcomes for targeted agents. They used a conventional dose-finding algorithm 
to identify the MTD in the first stage, followed by a dose-validation stage that examines the 
toxicity and efficacy profiles for the dose levels around the identified MTD. Simulation 
results show that this design performs well under the restrictive condition that the OBD is in 
the neighborhood of the MTD. However, if the OBD is far away from the MTD, the 
performance of this design remains unclear.
Our study is motivated by a phase I clinical trial conducted at the University of California at 
Los Angeles Medical Center [21]. The purpose of the trial is to find the OBD of the MTA 
celecoxib combined with erlotinib in patients diagnosed with advanced non-small cell lung 
cancer. Celecoxib is an inhibitor that targets the rate-limiting enzyme Cox-2, which can 
regulate cellular proliferation, migration and invasion. Twenty-two patients were enrolled 
and treated with celecoxib at dose levels ranging from 200 mg to 800 mg, combined with a 
fixed dose of erlotinib. Both toxicity and efficacy endpoints were measured during the trial. 
Toxicity was determined by the dose-limiting toxicity and efficacy was measured by the 
biological acticity of the urinary prostaglandin E-M (PGE-M). No patients experienced 
toxicity and the dosage of 600 mg of celecoxib was selected as the OBD because it was 
associated with the maximal decrease in PGE-M. As reported by the author, “a phase II trial 
of celecoxib at 600 mg bid and erlotinib versus erlotinib plus placebo is planned”[21], p. 
3387.
In this article, motivated by the celecoxib trial, we propose a Bayesian two-stage seamless 
phase I/II design to identify the OBD by jointly monitoring the toxicity and efficacy 
outcomes. This design comprises a dose-finding stage and a dose-validation stage. In the 
first stage, we use the Bayesian model averaging continual reassessment method (BMA-
CRM) [22] to monitor toxicity outcomes, and use an isotonic regression method for dose 
escalation based on efficacy outcomes. When the dose escalation ends, we employ a 
Dirichlet-multinomial distribution to jointly model the toxicity and efficacy outcomes and 
select the candidate set based on a toxicity-efficacy volume ratio. The candidate set is then 
advanced to the second stage of dose validation, where more patients are randomized to 
validate the candidate dose set and identify the OBD. We note that although the proposed 
design is inspired by a phase I trial evaluating MTAs, the application of the proposed design 
is not restricted to MTAs. Indeed, because we use the nonparametric isotonic regression 
method, which makes little assumption on the dose-efficacy curve, the proposed design is 
applicable to both MTAs and cytotoxic agents.
The remainder of the article is organized as follows. In Section 2, we propose the seamless 
phase I/II design. In Section 3, we present a simulation study to investigate the operating 
characteristics of the proposed design and compare it with other existing designs. We 
conclude with a discussion in Section 4.
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2. Seamless phase I/II design
2.1. The dose-finding stage
The proposed seamless design starts with a dose-finding stage to find the candidate doses 
with acceptable toxicity-efficacy profiles. Specifically, we use the BMA-CRM ([22]) to 
monitor the toxicity outcomes. This method initializes multiple parallel CRM models and 
then averages the estimates of toxicity probabilities using the BMA method to enhance the 
robustness of the conventional CRM. Let (d1, …, dJ) denote a set of J pre-specified 
increasing doses for the agent under investigation and define π̂jT as the BMA estimate of the 
toxicity rate at dose dj. Then, with the highest acceptable toxicity rate ϕT, we construct
as the admissible set of doses based on toxicity in the first stage.
After establishing , the next step is to implement dose escalation within the admissible 
set. We propose an isotonic regression method for dose escalation based on the efficacy 
outcomes. The purpose of the dose escalation procedure is to accumulate information for 
identifying the OBD, treat patients with doses that achieve a high therapeutic effect, and 
safeguard patients at the same time. We consider a unimodal or plateaued dose-efficacy 
curve. We define pjE as the efficacy rate at dose level j and denote K as the highest dose level 
within the admissible set . Our dose-escalation goal is to find the most efficacious dose 
with the admissible set , the dose level j* such that
(1)
We use the isotonic regression method to find dose j*. However, the original isotonic 
regression requires a pre-specified location of the mode j*, which is unknown in our setting. 
To overcome this limitation, we enumerate all K possible locations of j*. Then, at each 
specified location j* = l for l = 1, …, K, we take the double-sided isotonic regression [19, 
23 ] to fit the accumulated efficacy outcomes that satisfy the order constraint (1) and obtain 
the corresponding set of estimates  for j = 1, …, K. Then, we select j* with the least 
goodness-of-fit mean squared error
where p̄jE is the proportion estimate of pjE. With the identified j* in hand, our dose-
escalation procedure can be described as follows:
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1. Treat the first cohort of patients at the lowest dose level or at the 
physician-specified dose.
2. At the current dose level j, based on the toxicity outcomes, using the 
BMA-CRM to identify the admissible set .
3. Identify the dose level j* within the admissible set  as the dose with 
the highest therapeutic effect while still safeguarding patients.
4. If j* > j, escalate the dose level to j + 1; if j* < j, de-escalate the dose level 
to j−1. If j* = j, identify jh as the highest tried dose. Then, retain dose level 
j if j* < jh; otherwise, escalate to j + 1 to explore more dose levels.
5. Repeat steps 2 to 4 until the maximum sample size for the dose-finding 
stage is reached.
Note that the proposed dose-escalation approach models the toxicity and efficacy outcomes 
separately. Theoretically, these two endpoints can also be modeled jointly. However, 
considering that the number of patients treated at each dose is small at the beginning of the 
trial, empirical experience from recent studies indicates that the joint modeling approach 
adds computational complexity but does not improve the performance of the dose-finding 
study [24, 25 ]. However, when dose escalation ends, we have already accumulated certain 
information about both the toxicity and efficacy outcomes. Hence, to precisely evaluate the 
toxicity-efficacy profiles, a joint modeling approach is implemented hereafter to borrow 
strength across these two endpoints for the purpose of identifying the candidate set of doses 
and selecting the OBD.
We use the Dirichlet-multinomial distribution to jointly model the toxicity and efficacy 
outcomes [26]. In particular, let T = 0, 1 and E = 0, 1 denote the binary toxicity and efficacy 
outcomes. We define that among a total of nj patients treated at dose level dj, rjte of them 
have experienced the event (T = t, E = e) with the associated probability pjte = Pr(T = t, E = 
e|dj) for t, e = 0, 1. Denoting rj = (rj00, rj01, rj10, rj11) and pj = (pj00, pj01, pj10, pj11), we 
jointly model the toxicity and efficacy outcomes using the Dirichlet-multinomial distribution 
as
(2)
where αj = (αj00, αj01, αj10, αj11) is the hyperparameter and represents the prior information 
at dose level j. Then, after setting pjT = pj10 + pj11 and pjE = pj01 + pj11 as the marginal 
toxicity and efficacy rates, the posterior distributions of pj, pjT and pjE are
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(3)
The Dirichlet-multinomial model is used to estimate the joint toxicity-efficacy probabilities 
and build a measure to evaluate the OBD. Following Yin et al., [3], we use a three-
dimensional toxicity-efficacy volume ratio as the tradeoff measure that jointly evaluates the 
toxicity and efficacy outcomes. Specifically, at dose level j, after denoting γj = pj01/(1−pjT) 
as the probability of efficacy conditional on no toxicity, we define the three-dimensional 
volume ratio as
(4)
Based on this expression, ωj decreases when either pjE or γj increases. In addition, a 
decreased pjT can result in a decreased ωj. Therefore, a smaller ω is always preferred when 
identifying the OBD. By introducing γj, the volume ratio ωj incorporates the correlation 
between toxicity and efficacy into the consideration. Figure (1) illustrates how the value of 
ωj varies with the correlation between the efficacy and toxicity outcomes. We specify pjT = 
0.3, pjE = 0.2, 0.15 and let the correlation increase from −0.25 to 0.25. As shown in Figure 
(1), the correlation between efficacy and toxicity can significantly affect the value of ωj. In 
particular, the volume ratio increased when the correlation increased. In other words, given 
that there is no toxicity, a lower correlation is preferred rather than a higher correlation. That 
is because, as the correlation increases, the same pjE can result in a higher pjT, which 
indicates a lower γj and increases ωj. Based on Figure (1), we claim that ωj is an appropriate 
statistic for jointly measuring the OBD and a lower ωj indicates a better dose level. 
Specifically, the dose that yields the minimum estimate of ωj within the admissible set is 
declared as the OBD. Figure (2) expresses the contour plot of the volume ratio with different 
toxicity and efficacy probabilities. Figure (2) indicates that the volume ratio is a trade-off 
measure to establish a compromise between the efficacy and toxicity outcomes. For 
example, when the toxicity rate increases from 0.1 to 0.2 and further to 0.3, to keep the 
volume ratio at 1, the corresponding requirements for the efficacy rates are 0.26, 0.35 and 
0.41, respectively, when the correlation coefficient is fixed at 0.1.
At the end of the dose-finding stage, we identify the admissible set . Then, for each 
dose level j ∈ (1, ⋯, K) within the admissible set, we obtain the estimate of ωj (denoted as 
ω̂j). Given τ as the highest acceptable value of ωj, we build the candidate set of doses as
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By adding nj > 0, we tighten the safety evaluation of the trial by requiring that all the doses 
in the candidate set ℬ are tested by at least one cohort of patients during the dose-finding 
stage. We select τ = 8, which is calculated based on equation (4) with a highest acceptable 
toxicity rate pjT = 0.3, a lowest acceptable efficacy rate pjE = 0.2 and a speculated 
correlation coefficient of 0.1. Alternatively, if the correlation between the efficacy and 
toxicity is unknown, then we can use the data accumulated at the end of the dose-finding 
stage to estimate. Simulation studies indicate that the proposed design is not sensitive to the 
way that the correlation coefficient is determined (results not shown). Also, if the objective 
of the phase I/II trial is to compare a control treatment to the identified OBD, then we need 
to add the control arm to the candidate set ℬ. When the dose-finding stage ends, we 
seamlessly advance ℬ and trigger the dose-validation stage.
2.2. The dose-validation stage
Once the candidate set ℬ has been constructed, we seamlessly trigger the second stage of the 
trial for dose validation. The purpose of the dose-validation stage is to further validate the 
toxicity-efficacy profile of the candidate set and finally identify the OBD. To allocate 
patients during the second stage, we can use either approach: adaptive randomization or 
equal randomization. Adaptive randomization can shift the allocation of patients to more 
efficacious dose levels. However, the sample size in the phase I/II study typically is not 
large, which can yield less than the desired precision in estimating the treatment effect. 
Given this reason, we equally randomize the patients enrolled in the dose-selection stage to 
the candidate set. However, we note that the proposed design is not restricted to equal 
randomization and can easily accommodate adaptive randomization.
We continuously monitor the toxicity and efficacy outcomes during the dose-validation stage 
to update the candidate set ℬ by excluding any overly toxic or less efficacious dose. The 
same Dirichlet-multinomial distribution, (2) and (3), is used with nj to denote the patient 
data accumulating from the dose-finding stage until the current cohort of patients in the 
dose-validation stage. Hence, under the Bayesian framework, the Dirichlet-multinomial 
distribution seamlessly utilizes the accruing data in a “learn-as-we-go” fashion and thereby 
provides more precise estimates than single phase I and phase II trials conducted separately. 
The dose-validation procedure is summarized as follows:
1. Equally randomize a cohort of patients to the candidate set ℬ.
2. Update the posterior estimates of p̂jT and ωĵ within ℬ.
3. Drop any dose j with either p̂jT > ϕT or ω̂j > τ from ℬ. If all the doses have 
been dropped from the trial, terminate the trial early.
4. Repeat steps 1 to 3 until the maximum sample size for the dose-validation 
stage is reached.
Then, at the end of the dose-validation stage, the dose level with the minimum ωĵ is selected 
as the OBD. As the proposed design targets the OBD, we refer to it as the OBD-based 
design.
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In the dose-validation stage, we only drop doses from the trial due to toxicity and/or futility 
and do not terminate the trial for superiority. That is because when a dose is promising, for 
the purpose of enhancing the individual ethics of the trial, it is often preferred to enroll more 
patients into the trial. However, if desired, the proposed design can accommodate an early 
stopping rule for superiority. Specifically, let ρ be the criteria of the volume ratio for 
stopping early for superiority. Then, during the dose-validation stage, the trial is terminated 
early if any ω̂j < ρ, and that dose level j is then declared as the OBD.
In addition, to handle the control arm in the dose-validation stage, we need to keep the 
candidate set ℬ updated but not alter the control arm during the trial. We define δ > 0 as the 
marginal meaningful difference for ωj. Then, when the trial ends and the OBD is identified, 
we estimate the volume ratios for the OBD and the control treatment respectively (denoted 
as  and ω̂0). We conclude that the OBD is promising if ; otherwise, we conclude 
that the OBD is unpromising.
3. Simulation studies
3.1. Operating characteristics
We conducted comprehensive simulation studies to investigate the operating characteristics 
of the proposed OBD-based design under 6 scenarios with different toxicity and efficacy 
profiles. We compared the OBD-based design with an MTD-based design and the bCRM 
[15]. The MTD-based design mimics the seamless phase I/II design proposed by Hoering et 
al. [14, 20] and is a two-stage design that targets the MTD at the first stage. Specifically, the 
first stage of the MTD-based design uses the BMA-CRM to identify the MTD based solely 
on the toxicity outcomes. Then, at the second stage, the same dose-validation scheme is 
applied for 2 doses at and below the MTD to determine the OBD by jointly modeling and 
evaluating the toxicity and efficacy outcomes. The bCRM jointly models the toxicity-
efficacy outcomes through a flexible bivariate binomial distribution and adaptively allocates 
patients to the identified OBD throughout the phase I/II trial.
The maximum sample size in the simulation was 30 for the first stage and 120 for the second 
stage. The sample size was calibrated to maintain certain requirements for the dose selection 
percentages. In particular, we required at most 5% probability of selecting the incorrect 
doses if none dose was promising, and at least 50% probability of selecting the true OBD. 
We are aware that the conventional phase I/II trial typically requires a higher MTD selection 
percentage than 50%. However, considering that finding the OBD is generally more difficult 
due to the non-monotonic dose-efficacy relationship [19], we believe that 50% is an 
appropriate choice for the minimal requirement for identifying the OBD. Patients were 
enrolled into the trial in cohorts of size 3. We used the global cross-ratio model [27] to 
simulate the association between the toxicity and efficacy outcomes with the ratio fixed at 
1.5, which corresponds to a weak positive correlation coefficient of about 0.1 as suggested 
by Dienstmann et al.[28]. Notice that this cross-ratio model has been used in other phase I/II 
designs [3]. We fixed the ratio for the purpose of simplifying the simulation setting. 
However, we note that the proposed design can handle a varying ratio as well as no 
modification. We specified the highest acceptable toxicity rate as ϕT = 0.3 and the highest 
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acceptable volume ratio as ωj = 8 throughout the simulation. We also set the prior parameter 
αj = (0.25, 0.25, 0.25, 0.25) for the Dirichlet distribution at any dose level j. In addition, we 
used 5 skeletons in the BMA-CRM, with the following values:
Table 1 summarizes the simulation results based on 5,000 replicates, including the dose 
selection percentage, percentage of patients treated at each dose level, percentage of patients 
experiencing toxicity and efficacy, and average sample size of the whole trial (dose-finding 
stage + dose-validation stage). In Table 1, in addition to the toxicity and efficacy rates, we 
list the volume ratios for all the dose levels. The OBD, which obtains the minimum volume 
ratio while still safeguarding the patients, is emphasized by a boldface font. Notice that there 
can be 2 OBDs under some scenarios because the difference between the minimum volume 
ratio and the secondary minimum is negligible (within 0.1) in those scenarios.
Scenario 1 represents the circumstance in which there is no OBD. The OBD-based, MTD-
based and bCRM designs obtained 2.6%, 3.5% and 4.5% false positive rates, respectively. 
We also notice that the OBD-based design obtained the smallest average sample size of 30.4, 
suggesting that most of the trials were terminated at the end of the first stage.
Scenarios 2 and 3 simulated the unimodal dose-efficacy curve. All the doses are safe in 
scenario 2; whereas dose 5 is overly toxic in scenario 3. The OBD is located at doses 2 and 3 
in scenario 2 and at doses 1 and 2 in scenario 3. The OBD-based design outperformed the 
other designs in these scenarios. For example, in scenario 2, the OBD-based design had a 
satisfactory OBD selection percentage of 83.9% and allocated 68.5% of the patients to the 
OBD levels. Contrarily, the MTD-based and bCRM designs performed poorly, with 
respective OBD selection percentages of 6.7% and 20.5%, and respectively allocated only 
17.2% and 34.6% patients to the OBD levels. The OBD-based design enrolled as many as 
114.8 patients into the trial on average, which was 43.7 more patients than in the MTD-
based design and 28.9 more than in the bCRM design. Also, the OBD-based design reported 
the lowest toxicity rate of 7.9% and the highest efficacy rate of 28.4%. In other words, the 
OBD-based design obtained the best operating characteristics under that setting. The 
simulation results in scenario 3 were similar.
Scenarios 4 and 5 simulate the cases in which the efficacy rate initially increases with the 
dose level and then plateaus. The OBD is located at dose 2 for scenario 4 and at doses 2 and 
3 for scenario 5. The OBD-based design performed best in scenario 4. It yielded the highest 
OBD selection percentage of 52.8%; whereas the MTD-based design and bCRM design 
respectively achieved selection percentages of only 9.2% and 14.5%. For the allocation of 
patients, the OBD-based design allocated 37.0% of the patients to the OBD, which was 
27.3% higher than in the MTD-based design and 15.8% higher than in the bCRM design. In 
scenario 5, all the designs had approximately the same OBD selection percentage, and the 
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MTD-based design allocated around 15% more patients to the OBD than the other two 
designs. Scenario 6 mimics the traditional monotonically increasing dose-efficacy curve. 
According to the simulation results, the OBD-based design was still the best design in terms 
of OBD selection and patient allocation. In addition, the MTD-based design also obtained 
good performance in this scenario with an OBD selection percentage of 55.2% and 
allocating 63.6% of the patients to the OBD, which is only 3.7% less than the percentage of 
patients allocated to the OBD in the OBD-based design. A reasonable explanation for the 
plausible performances of the MTD-based design under the last two scenarios is that the 
MTD and the OBD are close to each other in these two scenarios. Specifically, dose 3 is not 
only the OBD but also the MTD under both scenario 5 and scenario 6. Consequently, the 
MTD-based design allocated more patients to dose level 3 and resulted in good 
performances in OBD (MTD) identification and patient allocation.
In summary, the OBD-based design is a robust design that performs well, regardless of the 
shape of the dose-efficacy curve. In contrast, the MTD-based and bCRM designs are 
sensitive to the shape of the dose-efficacy curve and the locations of the OBD and MTD. In 
particular, the MTD-based design obtains good performance when the OBD is in the 
neighborhood of the MTD, and the bCRM design performs well when a monotonically 
increasing dose-efficacy curve holds. If the dose-efficacy curve is unimodal and the OBD is 
not close to the MTD (e.g., scenarios 2 and 3), neither of the two alternative designs work 
well. As we typically know little about the dose-efficacy curve, we recommend the use of 
the OBD-based design in practice, especially for MTAs with possibly non-monotonic dose-
efficacy curves.
We stated that the OBD-based design can incorporate a control arm. To investigate this 
setting, we also conducted simulation studies of the OBD-based design when incorporating a 
control arm. As the bCRM cannot accommodate a control arm, the comparison was 
restricted to the OBD-based and MTD-based designs. Table 2 summarizes the simulation 
results. The same scenarios used in Table 1 appear in Table 2, except that we added a control 
arm with a toxicity rate of 0.25 and an efficacy rate of 0.2 in each scenario of Table 2. The 
simulation results were similar to the results shown in Table 1. When there was no 
promising dose (scenario 1), both designs selected the control arm with overwhelming 
percentages (over 95%). When the MTD and the OBD were different (scenarios 2, 3 and 4), 
the OBD-based design outperformed the MTD-based design. Otherwise, these two designs 
were comparable. In general, we still recommend the OBD-based design when a control arm 
is added.
3.2. Sensitivity analysis
We conducted a sensitivity analysis to investigate the performances of the OBD-based 
design with different criteria of early stopping for superiority, ρ and hyperparameter αj. 
Notice that all the simulated trials in Tables 1 and 2 did not stop for superiority (e.g., ρ = 0). 
However, as we mentioned earlier, by adding a positive value for ρ, the trial can stop early 
for superiority to reduce the sample size if any volume ratio ωj < ρ. Hence, it is of interest to 
study the performance of the OBD-based design under various values of ρ other than 0.
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Table 3 and Table 4 summarize the simulation results, with the former studying the original 
OBD-based design and the latter investigating the OBD-based design that incorporates a 
control arm. The results from these two tables are similar, so we focus on Table 3 hereafter. 
We take scenario 2 as an example. When there was no early stopping rule for superiority (ρ 
= 0), according to Table 1, the OBD-selection percentage was 89.3%, and 68.5% of the 
patients were allocated to the OBD levels. The average sample size was 114.8. This number 
dropped substantially to 49.0 when ρ = 0.25, according to the results in Table 3. Also, the 
OBD selection percentage and the proportion of patients treated at the OBD level decreased 
to 77.6% and 62.9% given ρ = 0.25. When ρ further increased from 0.25 to 1, the operating 
characteristics changed slightly, except that the average sample size decreased from 49.0 to 
33.5. This result shows a trade-off for adding the early stopping rule for superiority. On one 
hand, adding this rule can result in substantial saving related to the number of patients 
enrolled in the trial and the associated resources. On the other hand, the OBD selection 
percentage and the proportion of patients treated at the OBD decrease when this rule is 
added.
We use the Dirichlet-multinomial distribution to jointly model the toxicity-efficacy 
outcomes. We adopt the non-informative prior by selecting αj = (0.25, 0.25, 0.25, 0.25) for 
each dose level j. Conventionally, the non-informative prior is used when we lack 
information about a drug in advance of the trial. However, as a Bayesian design, it is also of 
interest to investigate the performance of the trial design with different prior information. To 
simplify the presentation, we use the prior parameters 
 and npri to represent the hyperparameter 
αj. The values of  and  can be viewed as the initial guesses of the toxicity and 
efficacy response rates at dose j, and npri can be viewed as the number of patients treated at 
each dose level before the trial begins. Therefore, at dose level j, given  and npri and 
assuming that the toxicity and efficacy outcomes are initially independent, the 
hyperparameter αj can be represented as
Hence, as npri increases, the prior distribution becomes more informative. Notice that the 
conventional prior αj = (0.25, 0.25, 0.25, 0.25) is equal to  and npri = 1, which 
corresponds to a non-informative prior.
We examined the operating characteristics of the OBD-based design with different prior 
distributions. In particular, we fixed  and varied the values of 
and npri. Table 5 summarizes these results. We adopted scenario 2 from Table 1 to simulate 
the trial. Although the true dose-efficacy shape is unimodal, to better investigate the prior 
sensitivity, we considered a wide range of the prior dose-efficacy shapes such as 
monotonically increasing, unimodal and plateaued. Also, we considered different prior 
sample sizes with npri varying from 0.5 to 5. Therefore, npri = 0.5 corresponds to an 
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extremely non-informative prior and npri = 5 corresponds to a relatively informative prior. 
Based on Table 5, we found the results to be rather stable across different priors, suggesting 
that the OBD-based design is not sensitive to the specification of the prior.
4. Discussion
In this article, we propose a two-stage seamless design for phase I/II clinical trials in which 
we jointly model the toxicity and efficacy outcomes and use a toxicity-efficacy trade-off 
measure to identify the optimal biological dose. An important advantage of the proposed 
design is that it imposes little shape assumption on the dose-efficacy curve. Consequently, 
the proposed design is robust and yields plausible performances across different shapes of 
the underlying true dose-efficacy curves. In addition, the proposed design is flexible in the 
sense that it can easily incorporate a control arm. The simulation results show that the 
proposed design has good performances for identifying the optimal biological dose. The R 
code to implement the proposed OBD-based design is available by contacting the first author 
of this article.
We select n1 = 30 and n2 = 120 as the maximum sample sizes for the first and second stages. 
These sample sizes were determined through calibration studies to maintain the desirable 
operating characteristics of the proposed design such as having a high chances of sending 
promising doses to the second stage and identifying the optimal biological dose at the end of 
the trial. We notice that this sample size is generally larger than the total sample size of two 
separate phase I and phase II trials. However, according to the simulation results in Table 1, 
when there is no promising dose, most trials that use the proposed design will terminate at 
the end of the first stage, which will result in a reduced sample size. On the other hand, 
when the optimal biological dose exists, we believe that a slightly larger trial can still be 
desirable because more patients can benefit within the trial. Nevertheless, if a small-scale 
trial is preferred, the proposed design can be easily extended by adding an early stopping 
rule for superiority. According to the simulations, the maximum sample size for the second 
stage can be substantially reduced by adding an early stopping rule.
The proposed design is appropriate for trials in which the toxicity and efficacy outcomes are 
both binary. It is worth studying how to extend the proposed designs to handle other types of 
response outcomes, such as multiple-grade toxicity or time to disease progression. We focus 
on phase I/II trials that evaluate a single agent. It is also of interest to extend the proposed 
design to drug combination trials. In this article, we fix the sample size at 30 for the dose-
finding stage; however, the proposed design can use various methods to adaptively alter the 
sample size of the first stage. One practical option is to specify a cut-off value such as ϕ = 
0.8 for the candidate dose set ℬ. Next, we need to update ℬ after each step of the dose-
escalation procedure. Then, if for every dose level j in ℬ we have the posterior probability 
P(ωj ≤ τ| ) > ϕ, we can terminate the dose-finding stage early and forward ℬ to the dose-
validation stage. In contrast, if the maximum sample size is reached but there are still certain 
dose levels in ℬ that do not meet the above condition, we can expand the cohorts for the 
dose-finding stage. This adaptive scheme enhances the flexibility of the phase I/II trial but 
also increases the computational burden. Further research in this area is warranted.
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Figure 1. 
Volume ratio with different correlation coefficient between efficacy and toxicity outcomes. 
The toxicity rate is fixed at pT = 0.3.
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Figure 2. 
Contour plot of the volume ratio ω with different toxicity and efficacy probabilities. The 
correlation coefficient is fixed at 0.1.
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